COMP <GO>
BMRN vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
BioMarin Pharmaceutical Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BMRN 6
— MRK 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: BMRN
LAST: $58.51 (+1.77%) • MKT CAP: $11.13B
balance-sheet
5.57
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMRN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMRN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.70% | 74.80% | +2.90 | BMRN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 20.70% | -14.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 15.3x | +5.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 6.51% | 3.42% | +3.09 | BMRN | /fcf-yield <GO> |
| Operating Margin | 12.70% | 34.30% | -21.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 28.10% | -17.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 12.90% | 1.30% | +11.60 | BMRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 5.57 | 5.19 | +0.38 | BMRN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.5 | 56.9 | -2.34 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.92 | +0.03 | BMRN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 18.4x | +8.40 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $361.02B | -$349.89B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMRN REV | MRK REV | BMRN GROSS % | MRK GROSS % | BMRN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | $65.01B | 77.7% | 74.8% | $725.0M | $12.36B |
| FY 2024 | $2.85B | $64.17B | 79.7% | 76.3% | $487.4M | $18.10B |
| FY 2023 | $2.42B | $60.12B | 44.0% | 44.0% | $50.4M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMRN // BETA 0.95
MRK // BETA 0.92